Cognitive decline in patients with Alzheimer's disease and its related factors in a memory clinic setting, Shanghai, China

PLoS One. 2014 Apr 21;9(4):e95755. doi: 10.1371/journal.pone.0095755. eCollection 2014.

Abstract

Objectives: Progressive cognitive decline is a characteristic hallmark of AD. It is important to identify prognostic markers to improve patient care and long-term planning. We aimed to identify the characteristics of disease progression in AD patients, focusing on cognitive decline and its related factors.

Methods: Clinically diagnosed AD patients in a memory clinic were followed. The mini-mental state examination (MMSE) and a battery of other neuropsychological tests were performed to assess the rate of cognitive decline and to analyze the related factors.

Results: A total of 165 AD patients were analyzed for cognitive changes. The MMSE scores declined at a rate of 1.52 points per year. Most neuropsychological test scores deteriorated significantly over time. Younger and early-onset AD patients deteriorated more rapidly than older and late-onset patients in global cognition and executive function. Men declined faster in memory but slower in attention than women. Higher education was associated with more rapid deterioration in visuo-spatial ability. Family history, hypertension and cerebral vascular disease were also associated with disease progression.

Conclusion: Attention, executive and visuo-spatial functions deteriorate at faster rates than other cognitive functions in AD patients. Age and age at onset were the main factors that associated with deterioration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / physiopathology*
  • China
  • Cognition Disorders / physiopathology*
  • Female
  • Humans
  • Hypertension / physiopathology
  • Male
  • Memory / physiology*
  • Neuropsychological Tests

Grants and funding

The study was supported by Natural Science Foundation of China (81200835), National 973 Project (2013CB530900, 2013CB530904, 2011ZX09307-001-03) and Eisai Co. Ltd. Eisai was not involved in the design and conduct of the study or in the data analysis and interpretation of the results.